Zobrazeno 1 - 10
of 250
pro vyhledávání: '"Elizabeth O, Hexner"'
Autor:
Matthew P. Connor, Neeharika Prathapa, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Ximena Jordan Bruno, Catherine E. Lai, Alison W. Loren, Selina M. Luger, Andrew H. Matthews, Shannon R. McCurdy, Alexander E Perl, David L. Porter, Arlene Zeringue, Joseph H. Oved, Timothy S. Olson, Keith W. Pratz, Daria V. Babushok
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/d008abed804247ba80e253a0d5516959
Autor:
Elizabeth O. Hexner
Publikováno v:
Haematologica, Vol 109, Iss 2 (2023)
Externí odkaz:
https://doaj.org/article/f7f3b78be55b4808be8b63f7a917ade4
Autor:
Igor Makhlin, Nicholas P. McAndrew, E. Paul Wileyto, Amy S. Clark, Robin Holmes, Lisa N. Bottalico, Clementina Mesaros, Ian A. Blair, Grace R. Jeschke, Kevin R. Fox, Susan M. Domchek, Jennifer M. Matro, Angela R. Bradbury, Michael D. Feldman, Elizabeth O. Hexner, Jacqueline F. Bromberg, Angela DeMichele
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-9 (2022)
Abstract Circulating IL-6, an activator of JAK/STAT signaling, is associated with poor prognosis and aromatase inhibitor (AI) resistance in hormone-receptor positive (HR+) breast cancer. Here we report the results of a phase 2 single-arm Simon 2-stag
Externí odkaz:
https://doaj.org/article/735547286a764f31ad3de14024a4e997
Autor:
Jason Gotlib, Andreas Reiter, Deepti Radia, Michael Deininger, Tracy George, Jens Panse, Alessandro Vannucchi, Uwe Platzbecker, Ivan Alvarez-Twose, Andrzej Mital, Olivier Hermine, Ingunn Dybedal, Elizabeth O. Hexner, Lambert Span, Ruben Mesa, Prithviraj Bose, Kirsten Pettit, Stephen Oh, Hui-Min Lin, Sasa Dimitrijevic, Javier Muñoz-González, Daniel J. Deangelo
Publikováno v:
HemaSphere, Vol 7, p e3184876 (2023)
Externí odkaz:
https://doaj.org/article/8d55f7aefc814a2483dddc9524d3fbe7
Autor:
Jian-Gang Ren, Bowen Xing, Kaosheng Lv, Rachel A. O’Keefe, Mengfang Wu, Ruoxing Wang, Kaylyn M. Bauer, Arevik Ghazaryan, George M. Burslem, Jing Zhang, Ryan M. O’Connell, Vinodh Pillai, Elizabeth O. Hexner, Mark R. Philips, Wei Tong
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 12 (2023)
RAS mutations are among the most prevalent oncogenic drivers in cancers. RAS proteins propagate signals only when associated with cellular membranes as a consequence of lipid modifications that impact their trafficking. Here, we discovered that RAB27
Externí odkaz:
https://doaj.org/article/636f9f226afa48728696c139c7a0044c
Autor:
Emily A. Blumberg, Julia Han Noll, Pablo Tebas, Joseph A. Fraietta, Ian Frank, Amy Marshall, Anne Chew, Elizabeth A. Veloso, Alison Carulli, Walter Rogal, Avery L. Gaymon, Aliza H. Schmidt, Tiffany Barnette, Renee Jurek, Rene Martins, Briana M. Hudson, Kalyan Chavda, Christina M. Bailey, Sarah E. Church, Hooman Noorchashm, Wei-Ting Hwang, Carl H. June, Elizabeth O. Hexner
Publikováno v:
JCI Insight, Vol 7, Iss 11 (2022)
BACKGROUND COVID-19 remains a global health emergency with limited treatment options, lagging vaccine rates, and inadequate healthcare resources in the face of an ongoing calamity. The disease is characterized by immune dysregulation and cytokine sto
Externí odkaz:
https://doaj.org/article/6597f6dab218404fa9ecd0f6232979e4
Autor:
Hrishikesh K. Srinagesh, Umut Özbek, Urvi Kapoor, Francis Ayuk, Mina Aziz, Kaitlyn Ben-David, Hannah K. Choe, Zachariah DeFilipp, Aaron Etra, Stephan A. Grupp, Matthew J. Hartwell, Elizabeth O. Hexner, William J. Hogan, Alexander B. Karol, Stelios Kasikis, Carrie L. Kitko, Steven Kowalyk, Jung-Yi Lin, Hannah Major-Monfried, Stephan Mielke, Pietro Merli, George Morales, Rainer Ordemann, Michael A. Pulsipher, Muna Qayed, Pavan Reddy, Ran Reshef, Wolf Rösler, Karamjeet S. Sandhu, Tal Schechter, Jay Shah, Keith Sigel, Daniela Weber, Matthias Wölfl, Kitsada Wudhikarn, Rachel Young, John E. Levine, James L.M. Ferrara
Publikováno v:
Blood Advances, Vol 3, Iss 23, Pp 4034-4042 (2019)
Abstract: The Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm probability (MAP), derived from 2 serum biomarkers, measures damage to crypts in the gastrointestinal tract during graft-versus-host disease (GVHD). We hypothesized that
Externí odkaz:
https://doaj.org/article/4646aec086e947a6b3b6196abc281ffa
Autor:
Matthew P. Connor, Alison W. Loren, Elizabeth O. Hexner, Mary Ellen Martin, Saar I. Gill, Selina M. Luger, James K. Mangan, Alexander E. Perl, Shannon R. McCurdy, Keith W. Pratz, Colleen Timlin, Craig W. Freyer, Alison Carulli, Christopher Catania, Jacqueline Smith, Lauren Hollander, Alexis M. Zebrowski, Edward A. Stadtmauer, David L. Porter, Noelle V. Frey
Publikováno v:
Transplantation and Cellular Therapy. 29:113-118
Patients with refractory or relapsed and refractory myeloid malignancies have a poor prognosis. Allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning (MAC) in patients with active, chemotherapy-refractory myeloid disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef5dc190078edd5f8225903761044691
https://doi.org/10.1016/j.jtct.2022.10.027
https://doi.org/10.1016/j.jtct.2022.10.027
Autor:
Alfred L. Garfall, Adam D. Cohen, Sandra P. Susanibar-Adaniya, Wei-Ting Hwang, Dan T. Vogl, Adam J. Waxman, Simon F. Lacey, Vanessa E. Gonzalez, Joseph A. Fraietta, Minnal Gupta, Irina Kulikovskaya, Lifeng Tian, Fang Chen, Natalka Koterba, Robert L. Bartoszek, Margaret Patchin, Rong Xu, Gabriela Plesa, Don L. Siegel, Andrea Brennan, Anne Marie Nelson, Regina Ferthio, Angela Cosey, Kim-Marie Shea, Rachel Leskowitz, Megan Four, Wesley V. Wilson, Fei Miao, Eric Lancaster, Beatriz M. Carreno, Gerald P. Linette, Elizabeth O. Hexner, Regina M. Young, Dexiu Bu, Keith G. Mansfield, Jennifer L. Brogdon, Carl H. June, Michael C. Milone, Edward A. Stadtmauer
Publikováno v:
Blood Cancer Discovery. 4:118-133
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af15a4e58dc3d2eade0573800002170e
https://doi.org/10.1158/2643-3230.bcd-22-0074
https://doi.org/10.1158/2643-3230.bcd-22-0074
Autor:
Craig W. Freyer, Daria V. Babushok, Noelle V. Frey, Saar I. Gill, Alison W. Loren, Selina M. Luger, Amit Maity, Mary Ellen Martin, John P. Plastaras, David L. Porter, Elizabeth O. Hexner
Publikováno v:
Transplantation and Cellular Therapy. 28:590-596
Allogeneic hematopoietic cell transplantation (alloHCT) is indicated for patients with intermediate-risk or high-risk myelofibrosis (MF) and remains the sole potential cure. Reduced-intensity conditioning (RIC) is commonly used because of older patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baeec43f964bec6e9adca74b34d1e5c1
https://doi.org/10.1016/j.jtct.2022.06.018
https://doi.org/10.1016/j.jtct.2022.06.018